Point72 Asset Management
SPRY icon

Point72 Asset Management’s ARS Pharmaceuticals SPRY Stock Holding History

Point72 Asset Management’s Portfolio SPRY Stock Details SPRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-5,238
Closed -$34.1K – 2742
2023
Q1 		$34.1K Buy
+5,238
New +$40.2K ﹤0.01% 1861
2021
Q3 		– Sell
-192,996
Closed -$5.96M – 1231
2021
Q2 		$5.96M Sell
192,996
-94,604
-33% -$3.03M 0.03% 578
2021
Q1 		$12.5M Buy
+287,600
New +$13.6M 0.06% 377

Other funds holding SPRY

DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Point72 Asset Management's SPRY Position: Q2 2023 in Review

Point72 Asset Management sold out of ARS Pharmaceuticals (SPRY) in Q2 2023, closing a stake of 5,238 shares — an estimated $34.1K sold.

Point72 Asset Management first reported a position in SPRY in Q1 2021 and held it in 3 quarters. The position peaked at $12.5M in Q1 2021. 92 funds tracked by Wall St. Rank hold SPRY as of Q2 2023.

  • Point72 Asset Management reported no remaining ARS Pharmaceuticals position as of Q2 2023 after selling out during the quarter.
  • Point72 Asset Management sold 5,238 ARS Pharmaceuticals shares in Q2 2023, an estimated $34.1K.
  • Point72 Asset Management first reported a position in ARS Pharmaceuticals in Q1 2021 and held it in 3 quarters.
  • Point72 Asset Management's ARS Pharmaceuticals position peaked at $12.5M in Q1 2021.
  • 92 funds tracked by Wall St. Rank held ARS Pharmaceuticals as of Q2 2023.

Based on Point72 Asset Management's 13F filing for Q2 2023, filed 14 Aug 2023.